Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.


Lung cancer is the leading cause of cancer deaths in the USA. Despite the development of new chemotherapy regimens, the prognosis remains poor. Several studies comparing various platinum-based regimens failed to produce a significant impact in the outcomes for patients with non-small cell lung cancer and this therapeutic modality appears to be reaching a… (More)


  • Presentations referencing similar topics